Halozyme Therapeutics, Inc. $HALO Shares Acquired by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 107,450 shares of the biopharmaceutical company’s stock after purchasing an additional 13,450 shares during the period. Hillsdale Investment Management Inc. owned 0.09% of Halozyme Therapeutics worth $7,231,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Larson Financial Group LLC increased its position in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the last quarter. Clearstead Advisors LLC increased its position in Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 265 shares during the last quarter. Harbour Investments Inc. increased its position in Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 372 shares during the last quarter. Penserra Capital Management LLC acquired a new position in Halozyme Therapeutics during the third quarter worth approximately $52,000. Finally, Wexford Capital LP acquired a new position in Halozyme Therapeutics during the third quarter worth approximately $70,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on HALO shares. Benchmark upped their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $80.67.

Halozyme Therapeutics Price Performance

HALO opened at $66.54 on Friday. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 52-week low of $51.06 and a 52-week high of $82.22. The company has a 50 day moving average of $66.14 and a two-hundred day moving average of $68.76. The company has a market cap of $7.89 billion, a P/E ratio of 23.94, a P/E/G ratio of 0.27 and a beta of 0.89.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. During the same period in the previous year, the firm earned $1.11 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, analysts expect that Halozyme Therapeutics, Inc. will post 7.6 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $69.19, for a total value of $691,900.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $53,122,698.20. This represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the transaction, the director owned 38,498 shares of the company’s stock, valued at $2,443,853.04. This trade represents a 4.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 120,482 shares of company stock worth $8,200,842 over the last ninety days. 2.50% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.